Other News To Note
Wednesday, February 9, 2011
PharmAthene Inc., of Annapolis, Md., presented pharmacokinetic data from its Valortim anthrax anti-toxin program at the 9th Annual ASM Biodefense and Emerging Diseases Research Meeting in Washington. The study was designed to compare the pharmacokinetics of Valortim following a single intravenous injection in nonchallenged cynomolgus macaques (cynos) to that in cynos infected with Bacillus anthracis. Results indicated that healthy animals had approximately a 45-fold increase in Cmax for a 40-fold increase in dose between 1 and 40 mg/kg and an approximately 34-fold increase in area under the curve. Infected animals had approximately a tenfold increase in Cmax for an eightfold increase in dose.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.